Journal of Cardiac Failure最新文献_第7页

Should Exogenous Ketone Body Supplementation Be Considered in Patients Hospitalized for Acute Heart Failure? Rationale and Design of the KETO-AHF Trial. 急性心力衰竭住院患者是否应考虑外源性酮体补充？KETO-AHF试验的基本原理和设计。

IF 8.2 2区医学

Journal of Cardiac Failure Pub Date : 2025-08-09 DOI: 10.1016/j.cardfail.2025.07.013

Kristoffer Berg-Hansen, Andreas Bugge Tinggaard, Roni Nielsen, Thomas Hvid Jensen, Nigopan Gopalasingam, Anders Hostrup Larsen, Niels Møller, Morten Böttcher, Malene Hollingdal, Mikael Kjær Poulsen, Lisbeth Antonsen, Toru Kondo, Pardeep S Jhund, Barry A Borlaug, Alexandre Mebazaa, Jacob Eifer Møller, Søren Vraa, Johannes Grand, Jens Dahlgaard Hove, Emil Wolsk, Morten Schou, Henrik Wiggers

{"title":"Should Exogenous Ketone Body Supplementation Be Considered in Patients Hospitalized for Acute Heart Failure? Rationale and Design of the KETO-AHF Trial.","authors":"Kristoffer Berg-Hansen, Andreas Bugge Tinggaard, Roni Nielsen, Thomas Hvid Jensen, Nigopan Gopalasingam, Anders Hostrup Larsen, Niels Møller, Morten Böttcher, Malene Hollingdal, Mikael Kjær Poulsen, Lisbeth Antonsen, Toru Kondo, Pardeep S Jhund, Barry A Borlaug, Alexandre Mebazaa, Jacob Eifer Møller, Søren Vraa, Johannes Grand, Jens Dahlgaard Hove, Emil Wolsk, Morten Schou, Henrik Wiggers","doi":"10.1016/j.cardfail.2025.07.013","DOIUrl":"10.1016/j.cardfail.2025.07.013","url":null,"abstract":"Background: Acute heart failure (AHF) is associated with high mortality rates, and contemporary medical treatments provide limited benefits in survival. Emerging evidence suggests that exogenous ketone bodies may have beneficial cardiovascular effects in patients with heart failure. The KETO-AHF (KETOne Supplements in Patients Hospitalized for Acute Heart Failure) trial is designed to assess the clinical benefits of initiating ketone supplementation with 1,3-butanediol compared with placebo in patients hospitalized for AHF with reduced ejection fraction.Methods: KETO-AHF is a multicenter, randomized, double-blind, placebo-controlled trial investigating the effects of 1,3-butanediol (33 g 3 times daily) in patients hospitalized for AHF. Patients with symptoms and signs of AHF requiring intravenous loop diuretics and/or vasoactive treatment, elevated natriuretic peptides, and a left ventricular ejection fraction ≤ 35%, whether de novo or known heart failure, will be enrolled within 5 days of hospital admission. Participants will be randomized 1:1 to receive either 1,3-butanediol or placebo for a 30-day treatment period. The study aims to enroll 125 patients in each group. The primary endpoint is a hierarchical composite of all-cause mortality, heart failure rehospitalization, 6-minute walk test improvement, and reduction in NT-proBNP levels at 30 days.Conclusion: The KETO-AHF trial will provide insights into the effects of supplementation with the ketone body 1,3-butanediol in patients hospitalized for AHF.","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144821544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes Among Pregnant Women With Hypertrophic Cardiomyopathy: Racial and Ethnic Differences in the United States. 肥厚性心肌病孕妇的结局：美国种族和民族差异

IF 8.2 2区医学

Journal of Cardiac Failure Pub Date : 2025-08-08 DOI: 10.1016/j.cardfail.2025.07.012

Duke Appiah, Oluwatobi E Oladeji, Eric K Broni, Imo A Ebong, Catherine Kim

引用次数: 0

Time-to-Diuretics in Acute Heart Failure Management: Striking the Balance Between Speed and Accuracy. 急性心力衰竭治疗中使用利尿剂的时间：在“速度”与“准确性”之间取得平衡。

IF 8.2 2区医学

Journal of Cardiac Failure Pub Date : 2025-08-08 DOI: 10.1016/j.cardfail.2025.07.011

Siamack Alam-Shoushtari, Nathaniel M Hawkins, Robert McKelvie, Stephanie Poon, George Honos, Shelley Zieroth, Justin Ezekowitz, Sean A Virani, Nima Moghaddam

引用次数: 0

Out-of-Sequence Donor Heart Allocation: A United Network for Organ Sharing Registry Analysis. 失序供体心脏分配：器官共享登记分析的联合网络。

IF 8.2 2区医学

Journal of Cardiac Failure Pub Date : 2025-08-07 DOI: 10.1016/j.cardfail.2025.07.009

Abigail R Benkert, Joseph B Lerman, Jacob N Schroder, Chetan B Patel, Adam D Devore, Kunal J Patel, Jeffrey E Keenan, Carmelo A Milano, Oliver K Jawitz

{"title":"Out-of-Sequence Donor Heart Allocation: A United Network for Organ Sharing Registry Analysis.","authors":"Abigail R Benkert, Joseph B Lerman, Jacob N Schroder, Chetan B Patel, Adam D Devore, Kunal J Patel, Jeffrey E Keenan, Carmelo A Milano, Oliver K Jawitz","doi":"10.1016/j.cardfail.2025.07.009","DOIUrl":"10.1016/j.cardfail.2025.07.009","url":null,"abstract":"Background: Out-of-sequence (OOS) allocation is a mechanism by which donor organs are offered outside the standard match run, typically to expedite the placement of hard-to-match or time-sensitive allografts. Rising OOS rates are described in abdominal organ transplantation, but limited data exist regarding OOS practices in heart transplantation.Methods: The United Network for Organ Sharing (UNOS) was used to identify all adult heart transplant recipients and corresponding donors between January 2015 and March 2024. The Potential Transplant Recipient file was then used to classify each donation as either in-sequence or out-of-sequence. We assessed temporal trends and practice patterns in relation to OOS allocation. Additionally, we evaluated donor and recipient characteristics and post-transplant survival outcomes.Results: Within the study period, there were 25,608 heart transplantations, of which 509 (2%) were from OOS donors. OOS allocation increased 2-fold over the study period (1.4%-3.1%). Use varied across Organ Procurement Organizations (OPOs) (0-5.4%) and transplant centers (0-16.7%), with a small subset of OPOs accounting for the majority of OOS allocations. Recipients of OOS-allocated allografts were more likely to be nonhospitalized older females with type O blood group. There was no significant difference in overall survival rates between OOS and in-sequence recipients at 1 year (93.1% vs 91.6%, respectively).Conclusions: OOS heart allocation, while rare, is increasing, and varies by geography and OPO. The OOS mechanism may provide an opportunity to improve organ recovery and support transplant access for harder-to-match candidates. However, standardization of OOS practices is needed to ensure equity in transplant access.","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Comparative Observational Study of Volume Status Monitoring in Patients With Implantable Pulmonary Artery Pressure Monitors and Intrathoracic Impedance Devices. 植入式肺动脉压监测仪和胸内阻抗装置对患者容量状态监测的比较观察研究。

IF 8.2 2区医学

Journal of Cardiac Failure Pub Date : 2025-08-07 DOI: 10.1016/j.cardfail.2025.07.010

Christopher M VAN Hove, Kevin G Buda, Mosi K Bennett

引用次数: 0

Effect of Time Since Heart Failure Diagnosis or Hospitalization on the Cost-Effectiveness of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. 心衰诊断或住院时间对达格列净治疗射血分数轻度降低或保留的心衰患者的成本-效果的影响

IF 8.2 2区医学

Journal of Cardiac Failure Pub Date : 2025-08-05 DOI: 10.1016/j.cardfail.2025.06.014

Ankeet S Bhatt, Rudolf A DE Boer, David Booth, Jason A Davis, Toru Kondo, Pardeep Jhund, Jieling Chen

引用次数: 0

Reassessing the need for primary prevention implantable cardioverter-defibrillators in contemporary patients with heart failure 重新评估当代心力衰竭患者对一级预防植入式心律转复除颤器的需求。

IF 8.2 2区医学

Journal of Cardiac Failure Pub Date : 2025-08-01 DOI: 10.1016/j.cardfail.2024.12.001

Ilan Goldenberg MD , Justin Ezekowitz MBBCh, MSc , Christine Albert MD, MPH, FHRS , Jeffrey D. Alexis MD , Lisa Anderson MD , Elijah R. Behr MD , James Daubert MD, FHRS , Katherine E. Di Palo PharmD, MBA, MS , Kenneth A. Ellenbogen MD, FHRS , Dillon J. Dzikowicz PhD , Eileen Hsich MD , David T. Huang MD, FHRS , James L. Januzzi MD , Valentina Kutyifa MD, PhD, FHRS , Anuradha Lala MD , Anekwe Onwuanyi MD , Ileana L. Piña MD, MPH , Roopinder K. Sandhu MD, MPH, FHRS , Samuel Sears PhD , Jakub Sroubek MD, FHRS , Javed Butler MD, MPH

{"title":"Reassessing the need for primary prevention implantable cardioverter-defibrillators in contemporary patients with heart failure","authors":"Ilan Goldenberg MD , Justin Ezekowitz MBBCh, MSc , Christine Albert MD, MPH, FHRS , Jeffrey D. Alexis MD , Lisa Anderson MD , Elijah R. Behr MD , James Daubert MD, FHRS , Katherine E. Di Palo PharmD, MBA, MS , Kenneth A. Ellenbogen MD, FHRS , Dillon J. Dzikowicz PhD , Eileen Hsich MD , David T. Huang MD, FHRS , James L. Januzzi MD , Valentina Kutyifa MD, PhD, FHRS , Anuradha Lala MD , Anekwe Onwuanyi MD , Ileana L. Piña MD, MPH , Roopinder K. Sandhu MD, MPH, FHRS , Samuel Sears PhD , Jakub Sroubek MD, FHRS , Javed Butler MD, MPH","doi":"10.1016/j.cardfail.2024.12.001","DOIUrl":"10.1016/j.cardfail.2024.12.001","url":null,"abstract":"<div><div>The main function of the implantable cardioverter-defibrillator (ICD) is to protect against sudden cardiac death (SCD) due to ventricular tachyarrhythmia (VTA). Current guidelines provide a recommendation to implant a prophylactic ICD for the primary prevention of SCD in individuals having heart failure with reduced ejection fraction (HFrEF) who never experienced a previous sustained VTA. However, these recommendations are based on clinical trials conducted more than 20 years ago and may not be applicable to contemporary patients with HFrEF who have a lower arrhythmic risk as a result of advances in heart failure medical therapies. Thus, there is an unmet need for more appropriate selection of contemporary patients with HFrEF for a primary prevention ICD. In this article, we review data underlying the current clinical equipoise on the need for routine implantation of a primary prevention ICD in patients with HFrEF and the rationale for conducting clinical trials that aim to reassess the role of the ICD in this population.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 8","pages":"Pages 1326-1338"},"PeriodicalIF":8.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-Up Acoramidis治疗转甲状腺素淀粉样心肌病：长期随访的开放标签扩展研究。

IF 8.2 2区医学

Journal of Cardiac Failure Pub Date : 2025-08-01 DOI: 10.1016/j.cardfail.2025.03.017

AHMAD MASRI MD, MS , MANDAR ARAS MD, PhD , MARTHA GROGAN MD , DANIEL JACOBY MD , MATHEW S. MAURER MD , SANJIV J. SHAH MD , RONALD WITTELES MD , PAUL W. WONG BS , ALAN X. JI PhD , JING DU MD, MS , SURESH SIDDHANTI PhD , LEONID KATZ MD , UMA SINHA PhD , JONATHAN C. FOX MD, PhD , DANIEL P. JUDGE MD

引用次数: 0

Supporting the Future of Heart Failure Care: HFSA’s Benefits for Early Career and Trainee Members 支持心力衰竭护理的未来：HFSA对早期职业和实习会员的好处

IF 8.2 2区医学

Journal of Cardiac Failure Pub Date : 2025-08-01 DOI: 10.1016/j.cardfail.2025.07.006

引用次数: 0

Screening for Undiagnosed Heart Failure: A Viewpoint 筛查未确诊心力衰竭：一个观点。

IF 8.2 2区医学

Journal of Cardiac Failure Pub Date : 2025-08-01 DOI: 10.1016/j.cardfail.2025.04.016

JOÃO PEDRO FERREIRA MD, PhD , FAIEZ ZANNAD MD, PhD

{"title":"Screening for Undiagnosed Heart Failure: A Viewpoint","authors":"JOÃO PEDRO FERREIRA MD, PhD , FAIEZ ZANNAD MD, PhD","doi":"10.1016/j.cardfail.2025.04.016","DOIUrl":"10.1016/j.cardfail.2025.04.016","url":null,"abstract":"<div><div>The syndrome of heart failure (HF) is characterized by a triad of (1) signs and symptoms, (2) cardiac alterations, and (3) natriuretic peptide elevation. Patients who exhibit alterations of cardiac structure or function without overt signs or symptoms of HF are staged as having “pre-HF.” However, many people with undiagnosed HF walk little and do not exercise; thus, they may be classified as having asymptomatic “pre-HF” simply because they never exercise enough to feel breathless. Moreover, many patients have comorbidities such as chronic obstructive pulmonary disease or obesity and the physical limitations may be attributed to the comorbidities rather than to HF. Such comorbidities may also influence natriuretic peptide measurements. The potential implications of an HF misdiagnosis are that many patients may remain undertreated. This is illustrated with data from the HOMAGE (Heart Omics in AGEing) study, which included asymptomatic people with mild natriuretic peptide elevation. When comparing patient characteristics, HOMAGE participants were similar to those of ALDO-DHF (Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients with Heart Failure with Preserved Ejection Fraction) who were classified as symptomatic patients with HF. Given the confluence of HF with several cardiac-renal and metabolic conditions, we propose a simplified, pragmatic, and inclusive approach for early HF diagnosis and treatment.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 8","pages":"Pages 1339-1344"},"PeriodicalIF":8.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0